Led · Equity · Apr 2026

Ascendance develops hybrid-electric propulsion, notably the Sterna powertrain, which it intends to sell to third parties and to use as the core propulsion system for its Atea VTOL aircraft. The company has begun final assembly of an initial Atea prototype and is targeting a first flight later this year. With the €12.2m France 2030 – Premiere Usine funding, Ascendance plans to accelerate series production of Sterna within its Muret L’Herm airfield facilities and later create a dedicated manufacturing site. That future facility is intended to allow a production ramp-up and progressive integration of civil and defence aircraft assembly. The announced government investment is structured over four years and is intended to move the company from prototype stage to production.

Led · Grant · Jul 2025

360Learning offers an AI-powered collaborative learning platform that helps organisations deliver targeted upskilling and reskilling at scale. Its AI workflows automate L&D tasks, enable subject-matter experts to share knowledge, and deliver personalised learning on the right device at the right time. The platform helps L&D teams identify in-house experts to co-create tailored training and close critical skills gaps. 360Learning will use a €1.8M French Government grant to accelerate R&D in AI-powered skills-based learning and expand its Paris-based team of software and machine-learning engineers. The company serves over 2,500 customers, including Michelin, Safran, Arkema, Malakoff Humanis, Symbio, AVOCarbon, and Wakam. Its stated mission is to deliver skills-based learning that drives business performance in France and across its global customer base. 360Learning provides a corporate learning platform that lets employees create and share courses, mix media, capture video, add questions, upload files and collaborate on content creation. The product emphasizes peer-to-peer learning and simple course creation so subject-matter experts can build training without e-learning expertise. Admins can distribute courses to all or specific groups, track completion rates and collect feedback. The company uses artificial intelligence to surface courses that need improvement and to match the right course with the right employee. Around 1,500 companies use the platform for onboarding, software training and skills development, including LVMH, Aircall, Toyota and Appen. Financially, 360Learning completed a $200 million funding round and had previously raised $40 million; it plans to hire more people, expand to new markets and pursue acquisitions. 360Learning offers a learning engagement platform that enables leaders and learners to collaboratively create, share and consume bite-size courses through a decentralized course-creation model rooted in the business. The platform emphasizes social learning and learning communities, with active engagement features that let anyone upload, edit and distribute content quickly. The company serves more than 1,200 enterprises across 160 countries and has about 150 employees across Paris, New York City and London. In April 2019 it secured a $41M Series B to support growth and product investment. The funds are earmarked to consolidate its leadership in France, accelerate expansion in the U.K. and North America, and build local-market presence with talent and offices in New York City and London. 360Learning also plans to accelerate product innovation and double its research and development investments.

Led · Grant · May 2025

Eligo Bioscience develops a proprietary topical gene delivery platform that enables in situ genetic engineering of skin-resident bacteria to act as localized bioreactors for therapeutic biologics. The company has published its microbiome base-editing platform in Nature and holds multiple foundational patents covering in situ editing of the skin microbiome. Its lead program is a first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris. Eligo recently expanded its Series B to $35 million and has now secured a $5 million non-dilutive grant from the French government to accelerate platform scaling and bioproduction. The grant is awarded under the France 2030 “Innovations in Biotherapies and Bioproduction” call and is operated by Bpifrance. Eligo is partnering with CDMO Biose Industries to optimize GMP microbial fermentation and scale its gene-delivery vector ahead of later-stage clinical trials, while expanding its pipeline into broader immuno-dermatology indications. Eligo Bioscience is a pioneering gene‑editing company focused on addressing diseases driven by the expression of bacterial genes from the human microbiome through in‑vivo delivery of genetic cargoes. Its core technology enables precise genetic modification within the microbiome, expanding the range of addressable genetic targets beyond traditional gene therapy and gene editing. Eligo is advancing a differentiated pipeline of precision medicines across immuno‑inflammation, oncology and infectious diseases, with its flagship program EB005 targeting moderate to severe acne vulgaris. The company plans to use new funding to complete pre‑IND and IND activities and to obtain early human data in a Ph1b/2a trial for EB005. Proceeds will also support expansion into other chronic diseases, including oncology, as Eligo moves toward clinical‑stage development. Eligo was founded by Luciano Marraffini, Timothy Lu, David Bikard and Xavier Duportet and has previously received venture backing from Sanofi Ventures, Khosla Ventures, Bpifrance and Seventure Partners. The company was named a Technology Pioneer by the World Economic Forum. Eligo Bioscience develops an eligobiotics platform that uses nanobots to engineer microbiomes for precision medicine interventions against bacteria-related diseases and to stem antibiotic resistance. The company positions its approach as enabling precise, targeted interventions on specific bacteria rather than using broad-spectrum antibiotics. New funding will be invested in further development of the platform and in expanding its team of engineers and scientists. Management intends to use the expanded team to begin clinical trials. Eligo raised a $20 million Series A from Khosla Ventures and Seventure Partners and secured a $2 million award from the Worldwide Innovation Challenge. The company was founded in Paris in 2014 by professors and alumni of MIT and Rockefeller University. Eligo Bioscience develops Eligobiotics, CRISPR-based antibiotics delivered via bacteriophage capsids to selectively target harmful bacteria while sparing beneficial microbiota. Led by CEO Xavier Duportet and based at Institut Pasteur in Paris, the company engineers CRISPR payloads to attack resistant pathogens. Their approach leverages beneficial microbiota to apply environmental pressure and halt infections. The technology has potential applications across human, animal, and agricultural microbiomes, including skin, mouth, vaginal and gut microbiomes. Eligo is a spin-off from MIT and Rockefeller University and recently completed a Series A financing of €2m led by Seventure; Sebastien Groyer joined the company’s board in conjunction with the round.

Led · Grant · Feb 2025

Abionyx Pharma is a biotech company based in Balma developing therapies to combat sepsis, with its lead investigational candidate CER-001 aimed at treating septic shock. The company has launched an €18.7M capital increase with preferential subscription rights and secured a subscription agreement with Fenja Capital for up to €14M in two tranches. Those financings provide immediate funding of €28.7M and could total €32.7M if the second tranche is exercised. Abionyx says the proceeds will be used to accelerate development of CER-001. No prior funding rounds or operating metrics were disclosed in the article.

Led · Equity · Dec 2024

Gleamer is a French med-tech company that builds artificial-intelligence tools to augment radiologists’ workflows. Its flagship platform, Gleamer Copilot, uses computer vision models to detect and quantify abnormalities on imaging studies. The company’s next product line, “OncoView,” will apply the same AI technology to oncology CT scans, initially targeting lung and bone metastases and later expanding to broader cancer imaging needs. Gleamer plans to invest €18 million over the next five years to develop a full suite of applications for lesion detection, measurement, and treatment-response monitoring. The project is being executed in partnership with leading French healthcare institutions and industrial collaborators, and is supported by a dedicated R&D team specializing in AI, data science, and clinical research. A €4.5 million government co-funding award under France’s “Digital Health” initiative will partially finance the effort, underscoring national recognition of the company’s technology and market leadership. Although operating metrics such as revenue or user count were not disclosed, management positions the company as a global leader in AI for medical imaging.